KBD102430

Phase I primary objectives: To evaluate the safety and tolerability of KBD102430 in participants of trials with advanced solid tumors; to evaluate dose-limiting toxicities (DLT) of KBD102430 in participants of trials with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and/or the recommended dose for Phase II (RP2D). Phase II primary objectives: To evaluate the efficacy of KBD102430 in participants of trials with HRR-mutant advanced solid tumors such as ovarian cancer, breast cancer, and prostate cancer. Exploratory objectives (applicable to Phase I/II): To explore the correlation between biomarkers and efficacy; to explore population pharmacokinetic (PopPK) analysis; to explore the relationship between exposure and efficacy and adverse events (AEs).